Arikayce

Arikayce for Nontuberculous Mycobacteria

The purpose of this randomized, placebo-controlled study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of liposomal amikacin for inhalation (LAI) versus placebo in patients with recalcitrant Mycobacterium avium complex lung disease. The primary outcome measure is proportion of subjects with culture conversion to negative.

Related Posts